Lothar Steidler

Summary

Affiliation: University College Cork
Country: Ireland

Publications

  1. ncbi request reprint Delivery of therapeutic proteins to the mucosa using genetically modified microflora
    Lothar Steidler
    University College Cork, Alimentary Pharmabiotic Centre, Transgenic Bacteriology, Cork, Ireland
    Expert Opin Drug Deliv 2:737-46. 2005
  2. ncbi request reprint Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10
    Lothar Steidler
    Department of Molecular Biomedical Research, Vlaams Interuniversitair Instituut voor Biotechnologie, Ghent University, KL Ledeganckstraat 35, B 9000 Ghent, Belgium
    Nat Biotechnol 21:785-9. 2003
  3. ncbi request reprint Genetically engineered probiotics
    Lothar Steidler
    Department of Medicine, Alimentary Pharmabiotic Center, University College Cork, Western Road, Cork, Ireland
    Best Pract Res Clin Gastroenterol 17:861-76. 2003
  4. ncbi request reprint Therapeutic drug delivery by genetically modified Lactococcus lactis
    Lothar Steidler
    Alimentary Pharmabiotic Centre, Transgenic Bacteriology, University College Cork, Western Road, Cork, Ireland
    Ann N Y Acad Sci 1072:176-86. 2006
  5. ncbi request reprint Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10
    Nathalie Huyghebaert
    Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium
    Eur J Pharm Biopharm 60:349-59. 2005
  6. ncbi request reprint Delivery of therapeutic proteins through Lactococcus lactis
    Sabine Neirynck
    Alimentary Pharmabiotic Centre, Transgenic Bacteriology Group, University College Cork, Western Road, Cork, Ireland
    Biotechnol Genet Eng Rev 22:253-66. 2006
  7. ncbi request reprint Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice
    Anouk Waeytens
    Department of Pathology, Ghent University, Ghent, Belgium
    Inflamm Bowel Dis 14:471-9. 2008
  8. ncbi request reprint Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis
    Nathalie Huyghebaert
    Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium
    Eur J Pharm Biopharm 59:9-15. 2005
  9. ncbi request reprint In situ delivery of cytokines by genetically engineered Lactococcus lactis
    Lothar Steidler
    VIB Ghent University, Department of Molecular Biology, KL Ledeganckstraat 35, B 9000 Gent, Belgium
    Antonie Van Leeuwenhoek 82:323-31. 2002
  10. pmc Characterization of ApuB, an extracellular type II amylopullulanase from Bifidobacterium breve UCC2003
    Mary O'Connell Motherway
    Department of Microbiology, Alimentary Pharmabiotic Centre and National University of Ireland, Cork, Western Road, Cork, Ireland
    Appl Environ Microbiol 74:6271-9. 2008

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Delivery of therapeutic proteins to the mucosa using genetically modified microflora
    Lothar Steidler
    University College Cork, Alimentary Pharmabiotic Centre, Transgenic Bacteriology, Cork, Ireland
    Expert Opin Drug Deliv 2:737-46. 2005
    ..This concept is being developed for the delivery of proteins to the intestine, but has also been applied in delivery to the vagina, nose and mouth...
  2. ncbi request reprint Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10
    Lothar Steidler
    Department of Molecular Biomedical Research, Vlaams Interuniversitair Instituut voor Biotechnologie, Ghent University, KL Ledeganckstraat 35, B 9000 Ghent, Belgium
    Nat Biotechnol 21:785-9. 2003
    ..lactis strain acquired an intact thyA gene from a donor such as L. lactis subsp. cremoris, the transgene would be eliminated from the genome...
  3. ncbi request reprint Genetically engineered probiotics
    Lothar Steidler
    Department of Medicine, Alimentary Pharmabiotic Center, University College Cork, Western Road, Cork, Ireland
    Best Pract Res Clin Gastroenterol 17:861-76. 2003
    ..If designed carefully and with absolute attention to biological safety in its broadest sense, the development of genetically modified probiotics has the potential to revolutionize alimentary health...
  4. ncbi request reprint Therapeutic drug delivery by genetically modified Lactococcus lactis
    Lothar Steidler
    Alimentary Pharmabiotic Centre, Transgenic Bacteriology, University College Cork, Western Road, Cork, Ireland
    Ann N Y Acad Sci 1072:176-86. 2006
    ..quot; This accomplishment has created the possibility of using this strategy for application in human medicine...
  5. ncbi request reprint Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10
    Nathalie Huyghebaert
    Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium
    Eur J Pharm Biopharm 60:349-59. 2005
    ..1 and 44.3% of initial viability after storage for 1 year at 8 and -20 degrees C, respectively, as well as its hIL-10 producing capacity...
  6. ncbi request reprint Delivery of therapeutic proteins through Lactococcus lactis
    Sabine Neirynck
    Alimentary Pharmabiotic Centre, Transgenic Bacteriology Group, University College Cork, Western Road, Cork, Ireland
    Biotechnol Genet Eng Rev 22:253-66. 2006
  7. ncbi request reprint Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice
    Anouk Waeytens
    Department of Pathology, Ghent University, Ghent, Belgium
    Inflamm Bowel Dis 14:471-9. 2008
    ..At present, many aspects of the exact mechanism by which the beneficial effect of the IL-10-producing L. lactis on the mucosa is mediated remain to be clarified...
  8. ncbi request reprint Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis
    Nathalie Huyghebaert
    Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium
    Eur J Pharm Biopharm 59:9-15. 2005
    ..lactis in the layering suspension did not significantly change viability after layering and storage. Interleukin-10 production capacity of L. lactis Thy12 was maintained after layering...
  9. ncbi request reprint In situ delivery of cytokines by genetically engineered Lactococcus lactis
    Lothar Steidler
    VIB Ghent University, Department of Molecular Biology, KL Ledeganckstraat 35, B 9000 Gent, Belgium
    Antonie Van Leeuwenhoek 82:323-31. 2002
    ..Therefore it can be attributed to the active in vivo delivery of IL-10. We have further documented this by demonstrating in situ de novo synthesis of IL-10 in the colon of IL-10 -/- mice...
  10. pmc Characterization of ApuB, an extracellular type II amylopullulanase from Bifidobacterium breve UCC2003
    Mary O'Connell Motherway
    Department of Microbiology, Alimentary Pharmabiotic Centre and National University of Ireland, Cork, Western Road, Cork, Ireland
    Appl Environ Microbiol 74:6271-9. 2008
    ....
  11. ncbi request reprint Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects
    Benoit Foligne
    Bactériologie des Ecosystémes, Institut Pasteur de Lille, Lille, France
    Dig Dis Sci 51:390-400. 2006
    ....
  12. ncbi request reprint A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease
    Henri Braat
    Department of Experimental Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands
    Clin Gastroenterol Hepatol 4:754-9. 2006
    ..However, treatment of patients with a living, genetically modified bacterium raises questions about the safety for human subjects per se and the biologic containment of the transgene...
  13. pmc Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance
    Sofie Termont
    Department for Molecular Biomedical Research, Flanders Interuniversity Institute for Biotechnology VIB and Ghent University, Technologiepark 927, B 9052 Ghent, Belgium
    Appl Environ Microbiol 72:7694-700. 2006
    ..The newly acquired properties should enable a larger proportion of the administered bacteria to reach the gastrointestinal tract in a bioactive form, providing a means for more effective mucosal delivery of therapeutics...
  14. ncbi request reprint Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization
    Christophe P Frossard
    University Hospital of Geneva, Department of Pediatrics, Geneva, Switzerland
    J Allergy Clin Immunol 119:952-9. 2007
    ..Because tolerance to food is potentially modulated by IL-10, strategies to prevent food allergy should favor an increased delivery of IL-10 to the gut...
  15. ncbi request reprint Live genetically modified bacteria as drug delivery tools: at the doorstep of a new pharmacology?
    Lothar Steidler
    Expert Opin Biol Ther 4:439-41. 2004
    ..Alongside conceptual proofs, the development of a robust system for biological containment will allow for the examination of genetically modified lactic acid bacteria as vectors of therapeutic protein delivery in human healthcare...
  16. ncbi request reprint Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice
    Klaas Vandenbroucke
    Department for Molecular Biomedical Research, Flanders Interuniversity Institute for Biotechnology and Ghent University, Belgium
    Gastroenterology 127:502-13. 2004
    ..However, orally administered TFF stick to the mucus of the small intestine and are absorbed at the cecum...
  17. ncbi request reprint Cytokines, chemokines and growth factors in the pathogenesis and treatment of inflammatory bowel disease
    Deborah O'Neil
    Department of Molecular Biology, Gheut University and Flanders Interuniversity Institute for Biotechnology, Gent, Belgium
    Adv Exp Med Biol 520:252-85. 2003